Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 1Glioblastoma 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × OKN 007 × 1 year × Clear all
NCT03587038 2025-12-10

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

University of Oklahoma

Phase 1 Active not recruiting
27 enrolled
CNS

Glioblastoma

NCT04388475 2025-08-12

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Oblato, Inc.

Phase 2 Completed
57 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡